Biologics and Injectable Billing (J-codes, 96372, 96401)

The two halves of the claim

• The drug line: the J-code, with units counted in the code's own billing unit — which is almost never one vial and almost never one milligram.
• The administration line: 96372 for a therapeutic, prophylactic or diagnostic subcutaneous or intramuscular injection; 96401 where the agent is a non-hormonal antineoplastic, which covers several intralesional dermatology agents.
• Intralesional injection of lesions is coded from the 11900 and 11901 family instead, selected by lesion count, and is not reported alongside 96372 for the same injection.
• Wastage from a single-dose container is reported on a separate line with modifier JW, and a single-dose container with no discarded amount carries modifier JZ.

Billing units are the most expensive detail

Every J-code defines its own billing unit, and the descriptor is the only authority. A code defined as one milligram billed as one unit for a 300 mg dose loses 299 units of payment; the same error inverted overbills by the same amount and is recovered on audit with interest. Practices that hard-code a unit count into an order set inherit that error on every dose until someone reconciles a remittance line against the descriptor.

Reconcile the drug line against three things: the descriptor's billing unit, the dose in the administration record, and the quantity actually drawn from inventory. Where all three agree, the claim is defensible. Where inventory and claim disagree over a period, that gap is either unbilled revenue or an inventory control problem, and both are worth finding.

Buy-and-bill versus specialty pharmacy

Under buy-and-bill the practice purchases the drug, carries the acquisition cost and the inventory risk, and bills the payer for both drug and administration. The margin can be meaningful, but so is the exposure: a denied dose is money already spent. Under specialty pharmacy the drug is shipped to the practice or the patient under the pharmacy benefit and the practice bills only the administration, which is safe and much smaller.

The decision is per drug and per payer, not per practice, and it should be revisited whenever a payer moves a product to a mandated pharmacy benefit. Continuing to buy-and-bill a product a payer has moved is a guaranteed denial that no appeal will recover.

Prior authorization is the real control point

• Authorization is drug-specific, dose-specific and duration-specific. A change in any of the three usually needs a new authorization even mid-course.
• Most dermatology biologic policies require documented severity, affected body surface area, and failure or intolerance of specified prior therapies with dates.
• Track the authorization expiry against the injection schedule, not against the calendar. A dose given three days after expiry is a full write-off.
• Record the authorization number, the approved units and the approved date range where the biller can see them before the dose is given, not after.